Efficacy and safety of methimazole in the treatment of hyperthyroidism due to graves disease in under 18 years. Barranquilla, 2013-2015
Keywords:
Methimazole, HperthyroidismAbstract
Objective: To evaluate the efficacy and safety of Methimazole in the treatment of hyperthyroidism due to Graves disease in patients younger than 18 years, in Barranquilla in the period January 2013 to April 2015. Materials and methods: Observational analytical study in 20 patients aged 1 to 18 years with confirmed hyperthyroidism due to Graves’ disease in the city of Barranquilla in January 2013 to April 2015 period attending the consultation of pediatric endocrinology (Dr. Jorge Luis Ordonez). Results: Females showed the highest rate with 75 %, mean age of 9.9 ± 2.8 years, goiter was the most frequent sign with 90 %; 100 % of patients admitted with TSH levels < 0.6 μU/ml, with a mean of 0.10 ± 0.25 μU/ml, at 18 months normalization was achieved in 80 % with a mean of 2.80 ± 2.27 μU/ml ( p = 0.0001). Conclusions: Treatment with Methimazole (0.4 mg/kg/day every 8 hours, maintenance 0.2 mg/kg/day every 8 hours; maximum dose: 30 mg) in patients under 18 diagnosed with hyperthyroidism due to illness Graves, is effective, as demonstrated by the appropriate response of TSH and free T4, and by decreasing the frequency of clinical signs.
Downloads
References
2. Godoy C, Acevedo M, Barrera A, Yismeyián A, Ugarte F. Hipertiroidismo en niños y adolescentes. Rev. chil. pediatr. 2009; 80(1): 21- 9.
3. Zanolli M, Araya A, Cattani A, Orellana P, Martínez A. Enfermedad de Basedow Graves en pacientes pediátricos. Rev Chil Pediatr 2008; 79: 26-35.
4. Muñoz M, Argente J. Fundamentos clínicos del hipertiroidismo en la infancia y la adolescencia. Horm Fact Crec. 2008; (12): 64-73.
5. Hung W, Sartis N. Autoinmune and non-autoinmune hyperthyroidism in pediatric patients: A review an personal commentary on management. Ped Endocrinol Rev. 2004; 2: 21-38.
6. Clayton GW. Thyrotoxicosis in children. In: Kaplan SA, editor. Clinical pediatric and adolescent endocrinology. Philadelphia: MB Sanders; 1982. p. 110-7.
7. Mayyayo E, Labarta J, Mar M. Enfermedad tiroidea. An Pediatr Contin. 2006; 4: 361-74.
8. Azizi F. The safety and efficacy of antithyroid drugs. Expert Opin Drug Saf. 2006; (5): 107- 116.
9. Caballero M, Muñoz M, López J, Argente J. Poliartritis severa asociada al tratamiento con Metimazol en paciente con enfermedad de Graves. An Pediatr. 2011; 75: 74-5.
10. Rivkees SA, Sklar CH, Freemark M. The management of Graves’ disease in children with special emphasis on radioiodine treatment. Clin Endocrinol Metab. 1998; 83: 3767-76.
11. Escobar Jiménez F, Luna López M, Fernández Soto ML, Quesada M, Glinoer D. Evolución de los criterios diagnósticos y terapéuticos en la enfermedad de Graves en España. Comparación de los resultados de dos encuestas realizadas en 1987 y 1995. Med Clin (Barc) 1998; 11: 205-10.
12. De Luis D, Arconada A, Aller R, Cuéllar L, Terroba M. Evolución clínica de una cohorte de pacientes con enfermedad de Graves- Basedow tratados con Metimazol. Med Clin (Barc) 2002; 118(20): 777-8.
13. Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves’ disease with antithyroid drugs. Thyroid 1998; 8: 119-24.
14. Cooper D. Antithyroid drugs in the management of patients with Graves Disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab 2003; 88: 3474-81.
15. Barrio R, Lopez-Capape M, Martinez-Bodás I, Carrillo A, Moreno JC, Alonso M, Alonso M. Graves’ disease in children and adolescent: Response to long-term treatment. Acta Paediatr. 2005; 94:1583-9.
16. Rodríguez Arnao MD, Clarence M, Cipei L, et al. Hipertiroidismo. En: Guías Diagnósticoterapéuticas en Endocrinología Pediátrica. Sociedad Española de Endocrinología Pediátrica; 2000.
17. Kaguelidou F, Carel JC, Léger J. Graves’ disease in childhood: Advances in management with antithyroid drug therapy. Horm Res. 2009; 71: 310-7.
